Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: Pandora’s Interim Analysis

Executive Summary

The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?


Related Content

Stockwatch: What Links Actimmune And Vertex’s Event Horizon?
Stockwatch: Fanning The Embers Of M&A
Imetelstat Study Blip Beats Geron’s Shares Down
Stockwatch: Damage Not Controlled
Third Time's The Charm? Orexigen Terminates CONVENE
FDA says Qinprezo not ready for NDA; Sunesis slammed
Intercept quiet on NASH safety data disclosure concerns


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst